Building Merger Consequence Models

Building Merger Consequence Models

When To Use

• Evaluating whether a proposed acquisition is accretive or dilutive to acquirer EPS
• Modeling pro forma combined financial statements for board presentations or fairness opinions
• Stress-testing deal structures across varying consideration mixes (cash vs. stock vs. mixed)
• Phasing synergy realization schedules for integration planning
• Analyzing purchase price allocation (PPA) impact on goodwill, intangibles, and future amortization
• Comparing multiple deal scenarios (e.g., different offer prices, financing structures, or synergy assumptions)

Inputs To Gather

Acquirer financials:

• Latest reported and consensus forecast EPS, net income, shares outstanding, share price
• Existing debt balances, interest rates, cash position, and tax rate
• Current P/E multiple and market capitalization

Target financials:

• Latest reported and consensus forecast EPS, net income, shares outstanding, share price
• Revenue and EBITDA for synergy sizing baseline
• Existing debt to be assumed or refinanced

Deal terms:

• Offer price per share or total equity value
• Consideration mix: % cash, % stock, any CVRs or earnouts
• Expected transaction and financing fees
• Assumed financing terms for any new debt (rate, tenor, amortization)

Synergy assumptions:

• Cost synergies: run-rate amount, phase-in schedule (typically 25%/50%/75%/100% over Years 1–4)
• Revenue synergies (if modeled): run-rate amount, phase-in, associated costs to achieve
• One-time integration/restructuring costs and their timing
• Tax treatment of synergies and integration costs

PPA estimates:

• Fair value step-ups for tangible and identifiable intangible assets
• Estimated useful lives for amortizable intangibles (customer relationships, technology, trade names)
• Deferred tax liability created by asset step-ups [VERIFY: tax rate and jurisdiction rules]

Workflow

1. Build standalone projections — Set up acquirer and target income statements on a consistent basis (same fiscal year, same line-item granularity). Calendarize if fiscal years differ. Normalize for non-recurring items.

2. Calculate purchase price and goodwill — Compute equity offer value, add assumed net debt to get enterprise value. Allocate purchase price: fair value of net tangible assets + identifiable intangibles + residual goodwill. Compute any deferred tax liabilities from step-ups.

3. Model financing structure — For cash consideration: determine funding source (cash on hand, new debt, or mix). Calculate incremental interest expense net of foregone interest income on cash used. For stock consideration: compute new shares issued using the exchange ratio (offer price / acquirer share price). For mixed deals: model both components.

4. Construct pro forma income statement — Combine acquirer + target standalone projections. Layer in adjustments:

   • (+) Cost synergies per phase-in schedule, net of tax
   • (+) Revenue synergies (if included), net of associated costs and tax
   • (−) Incremental intangible amortization from PPA
   • (−) Incremental interest expense from acquisition debt
   • (+) Interest income saved on target's refinanced debt (if applicable)
   • (−) One-time integration costs (typically excluded from recurring accretion/dilution but shown separately)
   • Apply blended effective tax rate to pre-tax adjustments [VERIFY: combined entity tax rate]

5. Calculate accretion/dilution — Compute pro forma EPS = pro forma net income / pro forma diluted shares outstanding. Compare to acquirer standalone EPS. Express result as % accretive or dilutive for each projection year. Show both with and without synergies to isolate synergy contribution.

6. Run sensitivity analysis — Build tables varying:

   • Offer price (±5–15% range)
   • Consideration mix (0%/25%/50%/75%/100% stock)
   • Synergy realization level (50%/75%/100%/125% of base case)
   • Interest rate on acquisition financing (±50–150 bps)
   • Breakeven synergy required to achieve EPS neutrality

7. Prepare output tables — Format results for presentation: summary accretion/dilution by year, pro forma EPS bridge (waterfall from standalone to pro forma), sensitivity matrices, and PPA summary.

Output

• Accretion/dilution summary: Year 1–3 (or longer) showing pro forma EPS vs. standalone EPS, $ and % impact, with and without synergies
• Pro forma income statement: Combined P&L with clearly labeled merger adjustments as separate line items
• EPS bridge / waterfall: Standalone acquirer EPS → target earnings contribution → synergies → financing cost → amortization → pro forma EPS
• Purchase price allocation table: Fair values assigned to tangible assets, identifiable intangibles (by category and useful life), goodwill, and associated deferred tax impacts
• Synergy phase-in schedule: Annual run-rate build, costs to achieve, and net after-tax contribution
• Sensitivity tables: Accretion/dilution across offer price, consideration mix, synergy level, and financing cost scenarios
• Key assumptions page: All inputs, sources, and items flagged [VERIFY]

Quality Checks

• EPS math integrity: Pro forma net income / pro forma shares = stated pro forma EPS (no rounding shortcuts)
• Shares outstanding consistency: New shares issued in stock deals = target shares × exchange ratio; verify diluted share count includes in-the-money target options converted at the exchange ratio
• Goodwill reasonableness: Total PPA should equal purchase price; goodwill should not be negative unless a bargain purchase is intended [VERIFY: bargain purchase gain treatment under ASC 805]
• Tax consistency: Verify the same tax rate is applied to synergies, amortization add-backs, and interest adjustments; confirm treatment of non-deductible goodwill
• Synergy double-counting: Ensure cost synergies are not also embedded in target's standalone projections
• Financing circularity: If using acquirer stock, confirm share price assumption is consistent (fixed vs. floating exchange ratio); if debt-funded, confirm interest rate reflects current market for acquirer's credit profile [VERIFY]
• Sign conventions: Accretive = positive (pro forma EPS > standalone); dilutive = negative — confirm this is consistent throughout all tables
• Cross-check: Compare implied transaction multiples (EV/EBITDA, P/E on offer) to precedent transactions for reasonableness